Navigation Links
Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates

EXTON, Pa., Oct. 1, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, among surveyed nephrologists, familiarity with Roche's Mircera, is low, but is still second highest among six late-stage renal therapies in development. Mircera is an erythropoietin receptor activator indicated for the treatment of symptomatic anemia in chronic kidney disease, which received FDA approval in November 2007. After reviewing a brief product profile, 49 percent of physicians are highly interested in Mircera and believe that over 40 percent of their chronic kidney disease–non-dialysis (CKD-ND) and 40 percent of dialysis patients are likely Mircera candidates.

(Logo: )

The TreatmentTrends®: US Nephrology Q3 2013 report also finds that surveyed nephrologists have extremely low familiarity with Injectafer—an IV iron product from American Regent approved in July 2013—as 70 percent report low familiarity. Interest among respondents is moderate and 25 percent of their CKD-ND patients are likely Injectafer candidates.

Mean familiarity ratings for Keryx Pharmaceutical's iron-based phosphate binder Zerenex increased significantly over the same quarter last year, likely because of the recent NDA submission and ongoing press and clinical activity. After reading a brief Zerenex product profile, most physicians expressed a preference to use it in dialysis patients versus CKD-ND patients.

"Mircera, Injectafer and Zerenex, coupled together, could have a significant impact on the U.S. renal anemia market in the coming years," said BioTrends Research Group Director Rob Dubman. "Mircera is a long-acting agent, which may provide greater patient convenience. And recent clinical trial results demonstrate that Ferinject—the brand name of Injectafer in Europe and elsewhere—reduces the need for other forms of anemia management such as erythropoietin stimulating agents (ESAs) and blood transfusions in CKD-ND patients with iron deficiency anemia. Lastly, Zerenex has been shown to reduce the need for ESAs and IV iron in dialysis patients in Phase 3 clinical data."

TreatmentTrends®: Nephrology (U.S.) is a syndicated quarterly report series, based on primary market research that provides a comprehensive view of the current and expected future management of renal anemia and bone and mineral metabolism in patients with chronic kidney disease. Topics include the percent of patients on each therapy, patient share, therapy initiation levels, laboratory values, attribute importance and product performance ratings, sales representative metrics, bundling, compliance and reaction (familiarity, interest and percentage of patients likely to be candidates) to new products in development. The Q3 2013 wave published in September 2013 and the Q4 2013 wave will publish in December 2013. A similar study on renal anemia, covering the major European markets, will publish in October 2013.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group 
Christopher Comfort 

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Therapy Device Improves Patient Comfort as They Recover From Shoulder Injuries
2. American Journal of Obstetrics and Gynecology Publishes PeriGen Research on Shoulder Dystocia
3. Cost vs. Reality - What CT Scanner Should I Choose?
4. What Men Should Know About Prostate Cancer -- But Dont
5. Home Affairs Committees Drugs Report: Angelus Foundation Says the Prime Minister Should Not Have Rejected a Royal Commission
6. Physician Patient Alliance for Health & Safety: CMS Quality Measures Should Include Continuous Electronic Monitoring of Patients Using Patient-Controlled Analgesia
7. 40 percent of parents give young kids cough/cold medicine that they shouldnt
8. Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises
9. Omthera Pharmaceuticals, Inc. Stockholders Seeking More Money, Information in Buyout Should Contact Deans & Lyons Law Firm
10. European Orthopedic Market 2017 Forecasts: Hip, Knee & Shoulder Analysis in New Research Report at
11. Sounds Like The Mesh Should Come Out!
Post Your Comments:
(Date:11/24/2015)... Nueva York , 24 de noviembre de ... del Avery Breathing Pacemaker System, se complace anunciar ... Ph.D. como consultor clínico. ... Foto -   ... Jonzon es un fisiólogo y consultor en neonatología ...
(Date:11/24/2015)... 2015 --> --> ... Market by Product Type (Bone Graft, Bine Graft Substitute, Platelet ... Posterior Lumbar Interbody Fusion), End User, and Geography - Global ... valued at $1.90 Billion in 2014 and is expected to ... during the forecast period of 2015 to 2020. ...
(Date:11/24/2015)... FRAMINGHAM, Mass. , Nov. 24, 2015   ... leading innovator of less-invasive, miniaturized circulatory support technologies that ... announced that President and Chief Executive Officer Doug ... Jaffray 27 th Annual Healthcare Conference on December ... being held December 1-2 in New York ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials ... the Narconon network, announced the release of a new cutting edge recovery program that ... has been working with drug- and alcohol-addicted individuals with the purpose to free addicts ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Smiles by ... TMJ Disorder, Bruxism, and moderate facial wrinkling. While many patients are aware of the ... the great success Botox® delivers to those suffering with discomfort, soreness, and pain as ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted ... in Chicago, IL, UV Angel is evaluating the efficacy of its product and its ... units (totaling 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, ...
(Date:11/25/2015)... ... 25, 2015 , ... In honor of Pulmonary Hypertension Awareness ... groups responsible for advancing care for pulmonary hypertension (PH) patients and helping to ... will receive special recognition throughout 2016 as part of PHA’s 25th anniversary celebrations. ...
(Date:11/25/2015)... MA (PRWEB) , ... November 25, 2015 , ... Many ... — fatigue, fuzzy-headedness, weight gain, cold hands, and dry skin. But many people who ... their diet and exercise regimen instead of their thyroid, especially if they don’t have ...
Breaking Medicine News(10 mins):